Musculoskeletal Inflammation – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Musculoskeletal Inflammation – Drugs In Development, 2024 report and make more profitable business decisions.
Musculoskeletal inflammation refers to the body’s response to irritation, injury, or infection affecting muscles, bones, joints, ligaments, or tendons. Conditions like arthritis, tendinitis, bursitis, or muscle strains often trigger this response. Inflammation manifests as pain, swelling, stiffness, and reduced mobility in the affected area. Causes vary—from overuse or trauma to autoimmune disorders like rheumatoid arthritis. Treatment aims to reduce inflammation and manage symptoms, involving rest, ice or heat therapy, medications (such as NSAIDs or corticosteroids), physical therapy, or lifestyle modifications. In chronic cases, ongoing management focuses on controlling inflammation to improve quality of life and maintain functionality.
The Musculoskeletal Inflammation drugs in development market research report provide comprehensive information on the therapeutics under development for Musculoskeletal Inflammation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Musculoskeletal Inflammation and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Musculoskeletal Inflammation | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 75 molecules, with 71 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Musculoskeletal Inflammation therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Musculoskeletal Inflammation pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Musculoskeletal Inflammation treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
3SBio IncAbbVie Inc
Acquist Theraputics Inc
Ajou University
Akaal Pharma Pty Ltd
Alma Bio Therapeutics
Arrowhead Pharmaceuticals Inc
Arthrosi Therapeutics Inc
Baylor College of Medicine
Boehringer Ingelheim International GmbH
C&C Research Laboratories
Causeway Therapeutics Ltd
Celixir Ltd
Changchun GeneScience Pharmaceutical Co Ltd
Chengdu Zeling Biomedical Technology Co Ltd
Deep Genomics Inc
DevaCell Inc
Dyve Biosciences Inc
Eisai Co Ltd
Eli Lilly and Co
Enzychem Lifesciences Corp
Evopoint Bioscience Co Ltd
Fochon Pharmaceutical Ltd
Fortress Biotech Inc
Fuji Yakuhin Co Ltd
Generoath Co Ltd
Hangzhou Grand Biologic Pharmaceutical Inc
Hinova Pharmaceuticals Co Ltd
Horizon Therapeutics Plc
Hunan Sanqing Pharmaceutical Co Ltd
IcanoMAB GmbH
Immunos Therapeutics AG
Insmed Inc
InventisBio Co Ltd
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
LG Chem Ltd
Merck KGaA
MRM Health NV
Nippon Chemiphar Co Ltd
Olatec Therapeutics LLC
ProAbTech Ltd
Protalix BioTherapeutics Inc
Quince Therapeutics Inc
Rigel Pharmaceuticals Inc
Shanghai Institute of Biological Products Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shanton Pharma Co Ltd
Stealth Biologics LLC
Suzhou Ribo Life Sciences Co Ltd
Swedish Orphan Biovitrum AB
Synlogic Inc
TaiwanJ Pharmaceuticals Co Ltd
Teijin Pharma Ltd
The United Laboratories International Holdings Ltd
Tianjin Institute of Pharmaceutical Research
Tonghua Dongbao Pharmaceutical Co Ltd
TWi Biotechnology Inc
Usynova Pharmaceuticals Ltd
Wellstat Therapeutics Corp
West Lake Biomedical Technology (Hangzhou) Co Ltd
Yale University
Youngene Therapeutics Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Musculoskeletal Inflammation reports